Education
About Us
Working with TipRanks
Follow Us
Stagezero Life Sciences (TSE:SZLS)
:SZLS
Total Valuation
StageZero Life Sciences Ltd has a market cap or net worth of C$4.94M. The enterprise value is C$6.19M.
Market CapC$4.94M
Enterprise ValueC$6.19M
Share Statistics
StageZero Life Sciences Ltd has 123,553,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding123,553,050
Owned by Insiders―
Owned by Institutions0.01%
Financial Efficiency
StageZero Life Sciences Ltd’s return on equity (ROE) is 1.52 and return on invested capital (ROIC) is 151.84%.
Return on Equity (ROE)1.52
Return on Assets (ROA)-16.29
Return on Invested Capital (ROIC)151.84%
Return on Capital Employed (ROCE)1.22
Revenue Per Employee94.88K
Profits Per Employee-285.38K
Employee Count40
Asset Turnover5.42
Inventory Turnover43.91
Valuation Ratios
The current PE Ratio of StageZero Life Sciences Ltd is -0.39. StageZero Life Sciences Ltd’s PEG ratio is 0.00.
PE Ratio-0.39
PS Ratio0.00
PB Ratio-0.59
Price to Fair Value-0.59
Price to FCF-1.25
Price to Operating Cash Flow-1.25
PEG Ratio0.00
Income Statement
In the last 12 months, StageZero Life Sciences Ltd had revenue of 3.80M and earned -11.42M in profits. Earnings per share was -0.11.
Revenue3.80M
Gross Profit-403.75K
Operating Income-7.75M
Pretax Income-11.42M
Net Income-11.42M
EBITDA-10.76M
Earnings Per Share (EPS)-0.11
Cash Flow
In the last 12 months, operating cash flow was -145.60K and capital expenditures 0.00, giving a free cash flow of -145.60K billion.
Operating Cash Flow-145.60K
Free Cash Flow-145.60K
Free Cash Flow per Share>-0.01
Dividends & Yields
StageZero Life Sciences Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.35
52-Week Price Change33.33%
50-Day Moving Average0.04
200-Day Moving Average0.04
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
StageZero Life Sciences Ltd upcoming earnings date is May 20, 2025, TBA Not Confirmed.
Last Earnings DateNov 12, 2024
Next Earnings DateMay 20, 2025
Ex-Dividend Date―
Financial Position
StageZero Life Sciences Ltd as a current ratio of 0.04, with Debt / Equity ratio of -23.99%
Current Ratio0.04
Quick Ratio0.02
Debt to Market Cap0.37
Net Debt to EBITDA-0.17
Interest Coverage Ratio-27.27
Taxes
In the past 12 months, StageZero Life Sciences Ltd has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
StageZero Life Sciences Ltd EV to EBITDA ratio is -0.57, with an EV/FCF ratio of -1.75.
EV to Sales1.63
EV to EBITDA-0.57
EV to Free Cash Flow-1.75
EV to Operating Cash Flow-1.75
Balance Sheet
StageZero Life Sciences Ltd has C$15.03K in cash and marketable securities with $2.13M in debt, giving a net cash position of C$2.12M billion.
Cash & Marketable SecuritiesC$15.03K
Total Debt$2.13M
Net CashC$2.12M
Net Cash Per ShareC$0.02
Tangible Book Value Per Share-C$0.08
Margins
Gross margin is -10.64%, with operating margin of -204.13%, and net profit margin of -300.79%.
Gross Margin-10.64%
Operating Margin-204.13%
Pretax Margin-300.79%
Net Profit Margin-300.79%
EBITDA Margin-283.49%
EBIT Margin-295.02%
Analyst Forecast
The average price target for StageZero Life Sciences Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―